JW
JWCTF.US JW (Cayman) Therapeutics Co. Ltd
- Market cap
- USD 84.3M
- P/E
- -
- P/B
- 1.25x
- ROE
- -44.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is JWCTF.US undervalued?
Graham numberThe Graham number of JW (Cayman) Therapeutics Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
JW (Cayman) Therapeutics Co. Ltd fundamental analysis
No fundamental analysis for JW (Cayman) Therapeutics Co. Ltd yet.
JW (Cayman) Therapeutics Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel in…
Full company profileJW (Cayman) Therapeutics Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
JW (Cayman) Therapeutics Co. Ltd annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 215K | 5.48M | 0.00 | 30.8M | 146M | 174M | 158M | 276M | 445M |
| Gross Profit | 215K | 5.48M | 0.00 | 9.05M | 58.8M | 88.2M | 77.3M | 119M | 231M |
| Operating Income | -112M | -204M | -441M | -759M | -856M | -790M | -459M | -242M | -372M |
| EBITDA | -112M | -186M | -444M | -723M | -752M | -656M | -489M | -160M | -247M |
| Net Income | -273M | -633M | -1.66B | -702M | -846M | -768M | -591M | -541M | -202M |
| EPS | -0.72 | -2.20 | -13 | -1.76 | -2.06 | -1.87 | -1.43 | -1.30 | -0.48 |
| Balance Sheet | |||||||||
| Total Assets | 341M | 669M | 3.78B | 3.12B | 2.79B | 2.15B | 1.68B | 987M | 833M |
| Total Liabilities | 654M | 1.61B | 350M | 326M | 437M | 462M | 511M | 431M | 381M |
| Shareholders' Equity | -313M | -942M | 3.43B | 2.79B | 2.35B | 1.68B | 1.17B | 557M | 452M |
| Cash & Short-term Investments | 134M | 255M | 2.63B | 1.84B | 1.39B | 1.01B | 757M | 503M | 392M |
| Total Debt | 58.7M | 77.8M | 124M | 147M | 279M | 319M | 422M | 263M | 255M |
| Cash Flow | |||||||||
| Operating Cash Flow | -106M | -189M | -261M | -561M | -537M | -398M | -333M | -76.8M | -350M |
| Capital Expenditure | 44.1M | 102M | 124M | 73.1M | 76.9M | 14.6M | 15.4M | 1.62M | 4.30M |
| Free Cash Flow | -150M | -291M | -385M | -634M | -614M | -413M | -349M | -78.5M | -354M |
| Ratios | |||||||||
| ROE | - | - | -48.5% | -25.2% | -35.9% | -45.6% | -50.5% | -97.2% | -44.6% |
| ROA | -80.0% | -94.7% | -44.0% | -22.5% | -30.3% | -35.8% | -35.1% | -54.8% | -24.2% |
| Net Profit Margin | -126,798.1% | -11,549.5% | - | -2,280.5% | -580.7% | -441.7% | -373.3% | -195.8% | -45.3% |
| Debt to Equity | - | - | 0.04x | 0.05x | 0.12x | 0.19x | 0.36x | 0.47x | 0.56x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
JW (Cayman) Therapeutics Co. Ltd dividends
JW (Cayman) Therapeutics Co. Ltd has not paid dividends in the last 8 fiscal years.
Who owns JW (Cayman) Therapeutics Co. Ltd
- Insiders 23.84%
- Institutions 0.25%
- Public & others 75.90%
- Shares outstanding 417M
- Free float 321M
JW (Cayman) Therapeutics Co. Ltd company profile
- Company name
- JW (Cayman) Therapeutics Co. Ltd
- Ticker
- JWCTF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 303
- Fiscal year end
- December
- Address
- Building B, Shanghai, China
- Phone
- 86 21 5078 3699
- Website
- jwtherapeutics.com
About JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection ("relma-cel") as a potential treatment for systemic lupus erythematosus ("SLE"), and progressed development of products for the treatment of solid tumors, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease. The company's products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases. It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC); JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients; JWATM213 for treating HCC; JWTCR001 for the treatment of various solid tumors; and JWCAR031 for the treatment of small cell lung cancer. In addition, the company engages in drug research and development; medical research and experimental development; import and export handling; and clinical trial and CRO, as well as investment holding activities. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
JW (Cayman) Therapeutics Co. Ltd management
7- Mr. Feng TianCEO & Executive Chairman · born 1978
- Dr. Yiping Li M.D.Co-Founder & Director · born 1964
- Ms. Jihua QinVP and Head of Marketing & Medical Affairs · born 1980
- Dr. Mark J. Gilbert M.D.Senior Advisor & Acting Chief Medical Officer · born 1961
- Mr. Chunan ChenSenior Vice President · born 1974
- Ms. Zhen XiaHead of Clinical Science Department · born 1980
- Ms. Ka Man Ng A.C.I.S., A.C.S.Company Secretary · born 1978